
Published
05 September 2011 | By Centrical Global Limited
Longer R&D timelines and the escalating costs of clinical trials, particularly in highly developed countries, has driven manypharmaceutical and biotechnology companies to examine the potential benefits of enrolling subjects in Eastern European countries. However, for many sponsors, operating in Eastern Europe can be a daunting prospect. In this article, we will examine how sponsors can be best positioned to take advantage of the benefits of emerging clinical trial locations.
As a registered user of PBR you can skip the majority of this form. Registration is FREE so register now or log in if you're already a member.
Fill In Details
By clicking the 'download white paper' button you agree to pass your details as shown to the white paper advertiser. The enquirer also permits the advertiser to follow up the enquiry by phone or email. PBR is in no way responsible for further communication between parties.
Fields marked * are compulsory
Fields marked * are compulsory